Shimizu W, McMahon B, Antzelevitch C
Masonic Medical Research Laboratory, Utica, New York 13501-1787, USA.
J Cardiovasc Electrophysiol. 1999 Feb;10(2):154-64. doi: 10.1111/j.1540-8167.1999.tb00656.x.
Sodium pentobarbital is widely used for anesthesia in experimental studies as well as in clinics, and it is known to prevent the development of torsades de pointes (TdP) in in vivo models of the long QT syndrome (LQTS).
This study examines the effects of pentobarbital on transmural dispersion of repolarization (TDR) and induction of TdP in arterially perfused canine left ventricular wedge preparations in which transmembrane action potentials were simultaneously recorded from epicardial, M, and endocardial regions using floating glass microelectrodes together with a transmural ECG. d-Sotalol and ATX-II were used to mimic the LQT2 and LQT3 forms of congenital LQTS. Both d-sotalol (100 micromol/L, n = 6) and ATX-II (20 nmol/L, n = 6) preferentially prolonged the action potential duration (APD90) of the M cell, thus increasing in the QT interval and TDR, and leading to the development of spontaneous and stimulation-induced TdP. In the absence and presence of d-sotalol, pentobarbital (10, 20, and 50 microg/mL) prolonged the APD90 of epicardial and endocardial cells, and, to a lesser extent, that of the M cell, thus prolonging the QT interval but reducing TDR. In the ATX-II model, the effects of pentobarbital on the QT interval and APD90 were biphasic: 10 microg/mL pentobarbital further prolonged APD90 of epicardial and endocardial cells more than that of the M cell; 20 to 50 microg/mL pentobarbital abbreviated the APD90 of epicardial and endocardial cells less than that of the M cell, thus abbreviating the QT interval and markedly reducing TDR. Twenty to 50 microg/mL pentobarbital totally suppressed spontaneous as well as stimulation-induced TdP in both models
Our data indicate that pentobarbital reduces TDR in control and under conditions of congenital and acquired LQTS, and suggest that this mechanism may contribute to the ability of the anesthetic to prevent the development of spontaneous as well as stimulation-induced TdP under conditions mimicking LQT2, LQT3, and acquired (drug-induced) forms of the LQTS. The data also serve to illustrate that there are circumstances under which QT prolongation may not be arrhythmogenic.
戊巴比妥钠在实验研究和临床中广泛用于麻醉,已知其可在长QT综合征(LQTS)的体内模型中预防尖端扭转型室速(TdP)的发生。
本研究检测了戊巴比妥对动脉灌注犬左心室楔形标本复极跨壁离散度(TDR)及TdP诱发的影响,在该标本中,使用漂浮玻璃微电极同步记录心外膜、M细胞和心内膜区域的跨膜动作电位以及跨壁心电图。使用d - 索他洛尔和ATX - II模拟先天性LQTS的LQT2和LQT3形式。d - 索他洛尔(100 μmol/L,n = 6)和ATX - II(20 nmol/L,n = 6)均优先延长M细胞的动作电位时程(APD90),从而使QT间期和TDR增加,并导致自发和刺激诱发的TdP发生。在不存在和存在d - 索他洛尔的情况下,戊巴比妥(10、20和50 μg/mL)延长了心外膜和心内膜细胞的APD90,对M细胞的延长程度较小,从而延长了QT间期但降低了TDR。在ATX - II模型中,戊巴比妥对QT间期和APD90的影响呈双相性:10 μg/mL戊巴比妥进一步延长心外膜和心内膜细胞的APD90,对M细胞的延长更多;20至50 μg/mL戊巴比妥缩短心外膜和心内膜细胞的APD90程度小于M细胞,从而缩短QT间期并显著降低TDR。20至50 μg/mL戊巴比妥在两个模型中均完全抑制了自发和刺激诱发的TdP。
我们的数据表明,戊巴比妥在对照以及先天性和获得性LQTS条件下均可降低TDR,并提示该机制可能有助于麻醉药在模拟LQT2、LQT3和获得性(药物诱导)LQTS形式的条件下预防自发和刺激诱发的TdP的发生。数据还表明,在某些情况下QT延长可能不会诱发心律失常。